133 related articles for article (PubMed ID: 16531720)
1. [A case of recurrent breast cancer with life-threatening multiple lung metastasis markedly responding to CMF as third-line chemotherapy].
Yoshino H; Kinoshita S; Emori N; Kadoya S; Hiranuma C; Ishiguro K; Koizumi H; Morita K; Bando H; Murakami N; Yamada T
Gan To Kagaku Ryoho; 2006 Mar; 33(3):365-7. PubMed ID: 16531720
[TBL] [Abstract][Full Text] [Related]
2. [A case of recurrent breast cancer with life-threatening liver metastasis remarkably responding to classical CMF].
Hasegawa S; Chishima T; Shimizu D; Ishikawa T; Ichikawa Y
Gan To Kagaku Ryoho; 2010 Mar; 37(3):507-9. PubMed ID: 20332693
[TBL] [Abstract][Full Text] [Related]
3. [Two cases of breast cancer markedly responded to neoadjuvant chemoendocrine therapy (2 cycles of CMF and tamoxifen, pCR and near pCR)].
Rai Y; Sagara Y; Sagara Y; Ooi Y
Gan To Kagaku Ryoho; 2004 Mar; 31(3):443-7. PubMed ID: 15045959
[TBL] [Abstract][Full Text] [Related]
4. [A case of anthracycline and taxane-resistant breast cancer with life-thereatening multiple liver metastases responding to oral combination chemotherapy by UFT, cyclophosphamide and medroxyprogesterone acetate].
Ishikawa T; Takashima T; Takagaki K; Ogawa Y; Onoda N; Nakata B; Kato Y; Hirakawa K
Gan To Kagaku Ryoho; 2005 May; 32(5):687-90. PubMed ID: 15918574
[TBL] [Abstract][Full Text] [Related]
5. Treatment of advanced breast cancer: How much chemotherapy is enough?
DiPaola RS; Kaufman A; Mikhail MM
Semin Oncol; 1996 Jun; 23(3):xv-xxii; discussion xxii-xxiv. PubMed ID: 8658211
[No Abstract] [Full Text] [Related]
6. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.
International Breast Cancer Study Group (IBCSG)
J Natl Cancer Inst; 2002 Jul; 94(14):1054-65. PubMed ID: 12122096
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
[TBL] [Abstract][Full Text] [Related]
8. [Adjuvant chemotherapy for breast cancer--a current controversy].
Jinno H; Ikeda T; Kubouchi K; Fujiwara K; Kitajima M
Gan To Kagaku Ryoho; 2004 Feb; 31(2):176-80. PubMed ID: 14997747
[TBL] [Abstract][Full Text] [Related]
9. An increase in cell number at completion of therapy may develop as an indicator of early relapse: quantification of circulating epithelial tumor cells (CETC) for monitoring of adjuvant therapy in breast cancer.
Pachmann K; Dengler R; Lobodasch K; Fröhlich F; Kroll T; Rengsberger M; Schubert R; Pachmann U
J Cancer Res Clin Oncol; 2008 Jan; 134(1):59-65. PubMed ID: 17611779
[TBL] [Abstract][Full Text] [Related]
10. Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: are all CMFs alike? The International Breast Cancer Study Group (IBCSG).
Goldhirsch A; Colleoni M; Coates AS; Castiglione-Gertsch M; Gelber RD
Ann Oncol; 1998 May; 9(5):489-93. PubMed ID: 9653488
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
; Castiglione-Gertsch M; O'Neill A; Price KN; Goldhirsch A; Coates AS; Colleoni M; Nasi ML; Bonetti M; Gelber RD
J Natl Cancer Inst; 2003 Dec; 95(24):1833-46. PubMed ID: 14679153
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant chemotherapy in early breast cancer.
Ejlertsen B
Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
[TBL] [Abstract][Full Text] [Related]
13. [Randomized comparative study of CMF (cyclophosphamide, methotrexate and 5-fluorouracil) and UFT-tamoxifen regimens as adjuvant chemotherapy after surgery for breast cancer: Tochigi Prefectural Study Group for Post-Breast Cancer Adjuvant Chemotherapy].
Tamura H; Kojima M; Kobayashi H; Ando J; Oka S; Fujisaki M; Wada N; Imoto S; Ikeda T
Gan To Kagaku Ryoho; 2000 Jul; 27(7):993-1002. PubMed ID: 10925684
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients.
International Breast Cancer Study Group
J Clin Oncol; 1997 Apr; 15(4):1385-94. PubMed ID: 9193330
[TBL] [Abstract][Full Text] [Related]
15. [Recent perspectives second-line chemotherapy for breast cancer].
Fujiuchi N; Ohokubo K; Saeki T; Sasaki Y
Gan To Kagaku Ryoho; 2005 Jan; 32(1):11-4. PubMed ID: 15675574
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis.
Fujii T; Le Du F; Xiao L; Kogawa T; Barcenas CH; Alvarez RH; Valero V; Shen Y; Ueno NT
JAMA Oncol; 2015 Dec; 1(9):1311-8. PubMed ID: 26402167
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant chemoendocrine therapy in postmenopausal breast cancer: cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. International Breast Cancer Study Group.
Goldhirsch A; Coates AS; Colleoni M; Castiglione-Gertsch M; Gelber RD
J Clin Oncol; 1998 Apr; 16(4):1358-62. PubMed ID: 9552037
[TBL] [Abstract][Full Text] [Related]
18. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.
Weiss RB; Woolf SH; Demakos E; Holland JF; Berry DA; Falkson G; Cirrincione CT; Robbins A; Bothun S; Henderson IC; Norton L;
J Clin Oncol; 2003 May; 21(9):1825-35. PubMed ID: 12721260
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P
Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820
[TBL] [Abstract][Full Text] [Related]
20. The expanding role of epirubicin in the treatment of breast cancer.
Glück S
Cancer Control; 2002; 9(2 Suppl):16-27. PubMed ID: 11965227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
